Partner with Hikma

Partnership drives our growth.

Together with our partners, we bring complex generics, branded/505(b)(2) products, specialty brands and biosimilars to patients across North America, Europe and MENA, through co-development, licensing and acquisitions.

Your partner in the MENA: One platform, 17 markets

Kareem Darwazah VP of Business Development & Alliance Management, MENA discusses how Hikma's on-the-ground presence and end-to-end capabilities give partners a single, trusted platform to bring innovative medicines and technologies across many therapeutic areas to patients, and to build lasting partnerships that grow over time.

Your partner for complex and specialty medicines in the US

Brett Bukvic, VP, Business Development and Pipeline Selection, explains how Hikma's end-to-end US expertise, continued investment in R&D and manufacturing, and a long record of successful launches help partners bring complex generics and specialty medicines, including injectables, semi solids, liquids, respiratory and nasal products, to market faster.

Newsroom

Latest partnership news

All news stories

Hikma launches NPH Otic Solution, USP Sterile in the US, in partnership with Orbicular

Press Release, Product

Hikma launches Glucentra® as the first generic semaglutide available to patients in Saudi Arabia

Press Release, Product

Hikma Pharmaceuticals and Marius Pharmaceuticals announce licensing agreement for KYZATREX® (testosterone undecanoate) C...

Press Release, Product

Hikma announces launch of Enoby™ (denosumab- qbde) and Xtrenbo™ (denosumab- qbde) referencing Prolia® and Xgeva® respect...

Press Release, Product
Related content

Explore more